TSO 500 ctDNA Version 2 delivers faster turnaround time, greater analytical sensitivity, more streamlined workflow, further enabling precision medicine. SAN DIEGO, Nov. 1, 2023 /PRNewswire/ -- ...
Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early detection plays a crucial role in reducing cancer-related morbidity and ...
Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC) ...
Evidence for plasma-based circulating tumor DNA (ctDNA) as a prognostic and predictive marker in urothelial carcinoma is helping to transform the diagnostic and management landscape. Joaquin Bellmunt, ...
Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early detection plays a crucial role in reducing cancer-related morbidity and ...
Circulating tumor DNA (ctDNA) saw more success in guiding adjuvant therapy decisions, in a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The phase 2 trial ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback